Evidence map›Paper›PMID 39789251›Full record

ArticleCardiovascular and interventional radiology2025

Comparative Analysis of Systemic Immune Responses and Metastatic Risks in Tumor Ablation: An Animal Study of Radiofrequency Ablation and Irreversible Electroporation with Immune Modulation.

Taiki Hirata, Katsutoshi Sugimoto, Ryoko Soya, Yoshinari Kikuchi, Yuki Kodama, Mayumi Ogawa, Koji Nagaoka, Kentaro Sakamaki, Takao Itoi, Kazuhiro Kakimi

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Cardiovascular and interventional radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Taiki HirataDepartment of Gastroenterology and Hepatology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-Ku, Tokyo, 1600023, Japan.
Katsutoshi SugimotoDepartment of Gastroenterology and Hepatology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-Ku, Tokyo, 1600023, Japan. sugimoto@tokyo-med.ac.jp.ORCID http://orcid.org/0000-0001-6271-7806
Ryoko SoyaDepartment of Gastroenterology and Hepatology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-Ku, Tokyo, 1600023, Japan.
Yoshinari KikuchiJapan Lifeline Co., Ltd, Tokyo, Japan.
Yuki KodamaJapan Lifeline Co., Ltd, Tokyo, Japan.
Mayumi OgawaJapan Lifeline Co., Ltd, Tokyo, Japan.
Koji NagaokaDepartment of Immunology, Faculty of Medicine, Kindai University, Osaka, Japan.
Kentaro SakamakiFaculty of Health Date Science, Juntendo University, Tokyo, Japan.
Takao ItoiDepartment of Gastroenterology and Hepatology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-Ku, Tokyo, 1600023, Japan.
Kazuhiro KakimiDepartment of Immunology, Faculty of Medicine, Kindai University, Osaka, Japan.

Funding

JSPS KAKENHI JP 21K07072
6 · The paper itself

Abstract

purposeThis study aimed to compare systemic immune responses and metastatic effects induced by radiofrequency ablation (RFA) and irreversible electroporation (IRE) in murine tumor models. We assessed cytokine production, growth of treated and untreated metastatic tumors, and synergy with immune checkpoint inhibitors (ICIs). MATERIALS AND

methodsHep55.1c murine hepatoma cells were implanted in C57BL/6N mice to establish primary tumors. In Experiment 1 (n = 50), RFA or IRE was applied to primary tumors, followed by CD8

resultsBoth techniques induced significant CD8

conclusionThe results of this animal study indicate that both techniques promote systemic anti-tumor immunity, though IRE uniquely induces an inflammatory response that risks exacerbating micro-metastases through IL-6. Combining IRE with IL-6 blockade may offer a promising strategy for nonthermal tumor ablation therapies. Further studies are warranted to refine ablation-immune therapy combinations for optimal therapeutic outcomes.

Indexed as

Carcinoma, HepatocellularElectroporationLiver NeoplasmsRadiofrequency AblationAnimalsCD8-Positive T-LymphocytesCell Line, TumorCytokinesDisease Models, AnimalImmune Checkpoint InhibitorsInterleukin-6MiceMice, Inbred C57BLNeoplasm MetastasisCytokinesImmune Checkpoint InhibitorsInterleukin-6Animal studyImmune responseInterleukin 6Irreversible electroporationRadiofrequency ablation

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.